Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (97)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hamilton, A.
Right arrow Articles by Piccart, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hamilton, A.
Right arrow Articles by Piccart, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:647-663, 2000
© 2000 European Society for Medical Oncology

other

The contribution of molecular markers to the prediction of response in the treatment of breast cancer: A review of the literature on HER-2, p53 and BCL-2

A. Hamilton and M. Piccart

Institut Jules Bordet Brussels, Belgium

Dr Anne Hamilton, MBBS, FRACP, Kaplan Comprehensive Cancer Center, NYU School of Medicine, Bellevue C&D Building, Room 556, 462 First Ave, New York, NY 10016, USA, E-mail: hamila01{at}gcrc.med.nyu.edu

Background: The selection of therapies for breast cancer is today based on prognostic features (chemotherapy, radiotherapy), hormone receptor status (hormonal therapy) and HER-2 status (trastuzumab therapy). HER-2, p53 and BCL-2 are tumour-related proteins that have the potential to further improve individualisation of patient management, by predicting response to chemotherapy, hormonal therapy and radiotherapy.

Materials and methods: This paper reviews the rationale for the use of these proteins as predictive factors, as well as the published literature addressing the use of each one to predict response to hormonal therapy, chemotherapy and radiotherapy.

Results: HER-2, p53 and BCL-2 remain inadequately assessed as predictive factors in breast cancer. HER-2 evaluation is required for the selection of patients for trastuzumab (Herceptin®) therapy, as trials of this therapy have been limited to HER-2 overexpressors. HER-2 overexpression may be predictive of resistance to hormonal therapy. Anthracy-clines are effective therapy for breast cancer regardless of HER-2 status, but patients whose tumours overexpress HER-2 appear to receive the greatest relative benefit from this therapy. Studies of HER-2 as a predictor of response to CMF and to radiotherapy are inconclusive at this time. No data yet exist to support the use of p53 or BCL-2 as predictive factors in the therapy of breast cancer.

Conclusions: At this point in time, there is inadequate evidence to support the use of HER-2, p53 or BCL-2 to guide the selection of hormonal therapy, chemotherapy or radiotherapy for breast cancer.

BCL-2, breast cancer, HER-2, p53, predictive factor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
F. Docquier, G.-X. Kita, D. Farrar, P. Jat, M. O'Hare, I. Chernukhin, S. Gretton, A. Mandal, L. Alldridge, and E. Klenova
Decreased Poly(ADP-Ribosyl)ation of CTCF, a Transcription Factor, Is Associated with Breast Cancer Phenotype and Cell Proliferation
Clin. Cancer Res., September 15, 2009; 15(18): 5762 - 5771.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. Galmarini, I. Treilleux, F. Cardoso, C. Bernard-Marty, V. Durbecq, D. Gancberg, M.-C. Bissery, M. Paesmans, D. Larsimont, M. J. Piccart, et al.
Class III {beta}-Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel
Clin. Cancer Res., July 15, 2008; 14(14): 4511 - 4516.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kyndi, F. B. Sorensen, H. Knudsen, M. Overgaard, H. M. Nielsen, and J. Overgaard
Estrogen Receptor, Progesterone Receptor, HER-2, and Response to Postmastectomy Radiotherapy in High-Risk Breast Cancer: The Danish Breast Cancer Cooperative Group
J. Clin. Oncol., March 20, 2008; 26(9): 1419 - 1426.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R Conforti, T Boulet, G Tomasic, E Taranchon, R Arriagada, M Spielmann, M Ducourtieux, J. Soria, T Tursz, S Delaloge, et al.
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
Ann. Onc., September 1, 2007; 18(9): 1477 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Perez, V. J. Suman, N. E. Davidson, S. Martino, P. A. Kaufman, W. L. Lingle, P. J. Flynn, J. N. Ingle, D. Visscher, and R. B. Jenkins
HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
J. Clin. Oncol., July 1, 2006; 24(19): 3032 - 3038.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Kroger, K. Milde-Langosch, S. Riethdorf, C. Schmoor, M. Schumacher, A. R. Zander, and T. Loning
Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients
Clin. Cancer Res., January 1, 2006; 12(1): 159 - 168.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. J. Burstein and E. P. Winer
HER2 or Not HER2: That Is the Question
J. Clin. Oncol., June 1, 2005; 23(16): 3656 - 3659.
[Full Text] [PDF]

Home page
 JCOHome page
F. Andre, A. Khalil, K. Slimane, C. Massard, M. C. Mathieu, S. Vignot, H. Assi, S. Delaloge, and M. Spielmann
Mitotic Index and Benefit of Adjuvant Anthracycline-Based Chemotherapy in Patients With Early Breast Cancer
J. Clin. Oncol., May 1, 2005; 23(13): 2996 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Andersson, L. Larsson, S. Klaar, L. Holmberg, J. Nilsson, M. Inganas, G. Carlsson, J. Ohd, C.-M. Rudenstam, B. Gustavsson, et al.
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF
Ann. Onc., May 1, 2005; 16(5): 743 - 748.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Milella, D. Trisciuoglio, T. Bruno, L. Ciuffreda, M. Mottolese, A. Cianciulli, F. Cognetti, U. Zangemeister-Wittke, D. Del Bufalo, and G. Zupi
Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene-Amplified Breast Cancer Cells
Clin. Cancer Res., November 15, 2004; 10(22): 7747 - 7756.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Madhusudan, A. Tamir, N. Bates, E. Flanagan, M. E. Gore, D. P. J. Barton, P. Harper, M. Seckl, H. Thomas, N. R. Lemoine, et al.
A Multicenter Phase I Gene Therapy Clinical Trial Involving Intraperitoneal Administration of E1A-Lipid Complex in Patients with Recurrent Epithelial Ovarian Cancer Overexpressing HER-2/neu Oncogene
Clin. Cancer Res., May 1, 2004; 10(9): 2986 - 2996.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Botti, S. Buglioni, M. Benevolo, D. Giannarelli, P. Papaldo, F. Cognetti, P. Vici, F. Di Filippo, F. Del Nonno, F. M. Venanzi, et al.
Altered Expression of FAS System Is Related to Adverse Clinical Outcome in Stage I-II Breast Cancer Patients Treated with Adjuvant Anthracycline-Based Chemotherapy
Clin. Cancer Res., February 15, 2004; 10(4): 1360 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
J. L. Brandsma, M. Shlyankevich, L. Zhang, M. D. Slade, E. C. Goodwin, W. Peh, and A. B. Deisseroth
Vaccination of Rabbits with an Adenovirus Vector Expressing the Papillomavirus E2 Protein Leads to Clearance of Papillomas and Infection
J. Virol., January 1, 2004; 78(1): 116 - 123.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Camilleri-Broet, A. C. Hardy-Bessard, A. Le Tourneau, D. Paraiso, O. Levrel, B. Leduc, S. Bain, H. Orfeuvre, J. Audouin, and E. Pujade-Lauraine
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group
Ann. Onc., January 1, 2004; 15(1): 104 - 112.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Ganem, M. Tubiana-Hulin, P. Fumoleau, M. Combe, J.-L. Misset, J.-M. Vannetzel, T. Bachelot, L. R. De Ybarlucea, V. Lotz, B. Bendahmane, et al.
Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer
Ann. Onc., November 1, 2003; 14(11): 1623 - 1628.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. S. Hendriks, L. K. Opresko, H. S. Wiley, and D. Lauffenburger
Coregulation of Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 (HER2) Levels and Locations: Quantitative Analysis of HER2 Overexpression Effects
Cancer Res., March 1, 2003; 63(5): 1130 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. M. Yousef, A. Scorilas, L. G. Kyriakopoulou, L. Rendl, M. Diamandis, R. Ponzone, N. Biglia, M. Giai, R. Roagna, P. Sismondi, et al.
Human Kallikrein Gene 5 (KLK5) Expression by Quantitative PCR: An Independent Indicator of Poor Prognosis in Breast Cancer
Clin. Chem., August 1, 2002; 48(8): 1241 - 1250.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
S. M. Ali, K. Leitzel, V. M. Chinchilli, L. Engle, L. Demers, H. A. Harvey, W. Carney, J. W. Allard, and A. Lipton
Relationship of Serum HER-2/neu and Serum CA 15-3 in Patients with Metastatic Breast Cancer
Clin. Chem., August 1, 2002; 48(8): 1314 - 1320.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. G. Schrama, I. F. Faneyte, J. H. Schornagel, J. W. Baars, J. L. Peterse, M. J. van de Vijver, O. Dalesio, H. van Tinteren, E. J. T. Rutgers, D. J. Richel, et al.
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up
Ann. Onc., May 1, 2002; 13(5): 689 - 698.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Lipton, S.M. Ali, K. Leitzel, L. Demers, V. Chinchilli, L. Engle, H. A. Harvey, C. Brady, C.M. Nalin, M. Dugan, et al.
Elevated Serum HER-2/neu Level Predicts Decreased Response to Hormone Therapy in Metastatic Breast Cancer
J. Clin. Oncol., March 15, 2002; 20(6): 1467 - 1472.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Fizazi, L. A. Martinez, C. R. Sikes, D. A. Johnston, L. C. Stephens, T. J. McDonnell, C. J. Logothetis, J. Trapman, L. L. Pisters, N. G. Ordonez, et al.
The Association of p21(WAF-1/CIP1) with Progression to Androgen-independent Prostate Cancer
Clin. Cancer Res., March 1, 2002; 8(3): 775 - 781.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Sjostrom, C. Blomqvist, K. von Boguslawski, N.-O. Bengtsson, I. Mjaaland, P. Malmstrom, B. Ostenstadt, E. Wist, V. Valvere, S. Takayama, et al.
The Predictive Value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for Chemotherapy Response in Advanced Breast Cancer
Clin. Cancer Res., March 1, 2002; 8(3): 811 - 816.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, and H.-J. Senn
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
J. Clin. Oncol., September 15, 2001; 19(18): 3817 - 3827.
[Full Text] [PDF]

Home page
 BMJHome page
M. Parton, M. Dowsett, and I. Smith
Studies of apoptosis in breast cancer
BMJ, June 23, 2001; 322(7301): 1528 - 1532.
[Full Text] [PDF]

Home page
 BMJHome page
J. Sjostrom and J. Bergh
How apoptosis is regulated, and what goes wrong in cancer
BMJ, June 23, 2001; 322(7301): 1538 - 1539.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.